Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Diagn Microbiol Infect Dis. 2023 Jan;105(1):115838. doi: 10.1016/j.diagmicrobio.2022.115838. Epub 2022 Oct 20.
Plasma cell-free metagenomic next-generation sequencing (cf-mNGS) is a non-invasive method that may be able to identify thousands of pathogens through a hypothesis-free approach. There is a lack of consensus on how this test compares to conventional microbiologic testing. We conducted a systematic review and meta-analysis of published studies evaluating the accuracy of plasma cf-mNGS in hospitalized patients and present pooled estimates of the positive (PPA) and negative percent agreement (NPA) compared to a composite reference standard that included all conventional microbiological testing and clinical history as assessed by an adjudication panel or clinical treatment team. Five retrospective studies (n = 552) were included. The majority of the patients (56%-88%) were immunocompromised. The pooled PPA was 67% (95% CI, 54%-81%) and the pooled NPA was 70% (95% CI, 63%-77%). The pooled diagnostic performance characteristics suggest that cf-mNGS provides limited evidence for ruling in or out the presence of infection as commonly used.
无细胞血浆宏基因组下一代测序(cf-mNGS)是一种非侵入性方法,通过假设自由的方法,可能能够鉴定数千种病原体。目前,对于该检测方法与传统微生物检测相比如何,尚无共识。我们对评估住院患者血浆 cf-mNGS 准确性的已发表研究进行了系统回顾和荟萃分析,并针对复合参考标准(包括所有传统微生物学检测和经裁决小组或临床治疗团队评估的临床病史)汇总了阳性预测值(PPA)和阴性预测值(NPA)的合并估计值。共纳入了五项回顾性研究(n=552)。大多数患者(56%-88%)存在免疫功能低下。汇总的 PPA 为 67%(95%CI,54%-81%),汇总的 NPA 为 70%(95%CI,63%-77%)。汇总的诊断性能特征表明,cf-mNGS 提供了有限的证据来普遍确定或排除感染的存在。